In vitro and in vivo assessment of the potential of Escherichia coli phages to treat infections and survive gastric conditions
dc.contributor.author | Kaczorowska, Joanna | en |
dc.contributor.author | Casey, Eoghan | en |
dc.contributor.author | Lugli, Gabriele A. | en |
dc.contributor.author | Ventura, Marco | en |
dc.contributor.author | Clarke, David J. | en |
dc.contributor.author | van Sinderen, Douwe | en |
dc.contributor.author | Mahony, Jennifer | en |
dc.contributor.funder | Bill and Melinda Gates Foundation | en |
dc.contributor.funder | Science Foundation Ireland | en |
dc.date.accessioned | 2023-11-16T14:17:26Z | |
dc.date.available | 2023-11-16T14:17:26Z | |
dc.date.issued | 2021 | en |
dc.description.abstract | Enterotoxigenic Escherichia coli (ETEC) and Shigella ssp. infections are associated with high rates of mortality, especially in infants in developing countries. Due to increasing levels of global antibiotic resistance exhibited by many pathogenic organisms, alternative strategies to combat such infections are urgently required. In this study, we evaluated the stability of five coliphages (four Myoviridae and one Siphoviridae phage) over a range of pH conditions and in simulated gastric conditions. The Myoviridae phages were stable across the range of pH 2 to 7, while the Siphoviridae phage, JK16, exhibited higher sensitivity to low pH. A composite mixture of these five phages was tested in vivo in a Galleria mellonella model. The obtained data clearly shows potential in treating E. coli infections prophylactically. | en |
dc.description.sponsorship | Bill and Melinda Gates Foundation (OPP1150567) | en |
dc.description.status | Peer reviewed | en |
dc.description.version | Published Version | en |
dc.format.mimetype | application/pdf | en |
dc.identifier.articleid | 1869 | en |
dc.identifier.citation | Kaczorowska, J., Casey, E., Lugli, G.A., Ventura, M., Clarke, D.J., Van Sinderen, D. and Mahony, J. (2021) ‘In vitro and in vivo assessment of the potential of escherichia coli phages to treat infections and survive gastric conditions’, Microorganisms, 9(9), 1869 (15pp). doi: 10.3390/microorganisms9091869 | en |
dc.identifier.doi | 10.3390/microorganisms9091869 | en |
dc.identifier.endpage | 15 | en |
dc.identifier.issn | 2076-2607 | en |
dc.identifier.issued | 9 | en |
dc.identifier.journaltitle | Microorganisms | en |
dc.identifier.startpage | 1 | en |
dc.identifier.uri | https://hdl.handle.net/10468/15238 | |
dc.identifier.volume | 9 | en |
dc.language.iso | en | en |
dc.publisher | MDPI | en |
dc.relation.ispartof | Microorganisms | en |
dc.relation.project | info:eu-repo/grantAgreement/SFI/SFI Starting Investigator Research Grant (SIRG)/15/SIRG/3430/IE/Phage-host interactome of the dairy bacterium Streptococcus thermophilus (PHIST)/ | en |
dc.relation.project | info:eu-repo/grantAgreement/SFI/SFI Investigator Programme/13/IA/1953/IE/Functional analysis of the host adsorption and DNA injection processes of a lactococcal bacteriophage/ | en |
dc.rights | © 2021, by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/) | en |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en |
dc.subject | Phage therapy | en |
dc.subject | Prophylactic | en |
dc.subject | Infections | en |
dc.subject | Galleria mellonella | en |
dc.subject | Diarrheagenic Escherichia coli | en |
dc.title | In vitro and in vivo assessment of the potential of Escherichia coli phages to treat infections and survive gastric conditions | en |
dc.type | Article (peer-reviewed) | en |
dc.type | journal-article | en |
oaire.citation.issue | 9 | en |
oaire.citation.volume | 9 | en |